Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer

Cancer Targeted Technology announced that the National Cancer Institute awarded the Phase I portion of the fast track Phase I/II Small Business Innovation Research grant to develop a new drug to treat metastatic prostate cancer.